DUETACT (Glimepiride; Pioglitazone Hydrochloride) Patent Expiration, LOE Window & CMS Spending

DUETACT (Glimepiride; Pioglitazone Hydrochloride) by Takeda: FDA Orange Book core substance LOE 2028-06-08, 1 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN021925 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-06-08
Last Listed Patent or Exclusivity Date2028-06-08
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.